This review concluded that, for every 25 babies born before 32 weeks of gestation and given nasal continuous positive airway pressure (CPAP), instead of intubation, one more survived without bronchopulmonary dysplasia until 36 weeks corrected gestation. The trials recruited women with stable pregnancies, who received antenatal steroids; the conclusion seems reliable, but may not be generalisable to less stable pregnancies.
In the included trials, babies were delivered at between 24 and 29 weeks of gestation. Their mean birth weight by treatment group ranged from 825g to 1,053g. All except one study randomised babies to treatment, after delivery. Thresholds for treatment with surfactant or intubation ranged from 40% to 60% oxygen. Because antenatal consent was required for enrolment, the babies were from more stable pregnancies; this was reflected in the fact that 95% of babies had received antenatal steroids.
More than one reviewer was involved in selecting the trials for inclusion.
Assessment of study quality
The trials were assessed using the Cochrane risk of bias tool. Two reviewers carried out this assessment independently; disagreements were resolved in consultation with a third reviewer.
Data extraction
The data were extracted to calculate relative risks or mean differences, with 95% confidence intervals. As well as the two primary outcomes, relative risks were calculated for a composite outcome of death or bronchopulmonary dysplasia.
Two reviewers independently extracted the data, using a standardised form; disagreements were resolved in consultation with a third reviewer.
Methods of synthesis
Pooled relative risks or weighted mean differences, with 95% confidence intervals, were calculated using a randomeffects model. Risk differences were calculated. Heterogeneity was explored and assessed using Χ² and Ι².
The number needed to treat (NNT) was calculated where the pooled estimates of relative risk indicated a statistically significant difference between groups.
